Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation

Table 5 Clinicopathological characteristics in palliative treatment group between sorafenib and sirolimus treatment group and other treatment group n (%)

Factors	Sorafenib + Sirolimus	Other treatments	P value
Recipient age1	55.3 ± 9.1	51.6 ± 6.9	0.179
Recipient sex, male	9 (75.0)	24 (88.9)	0.348
Etiology, Hepatitis B	10 (83.3)	22 (81.5)	0.369
MELD score1	9.3 ± 3.3	14.0 ± 9.7	0.033
GRWR1	1.40 ± 0.27	1.23 ± 0.25	0.065
AFP at transplantation1	1038.3 ± 1849.2	256.5 ± 361.1	0.173
HCC characteristics at pathology
Number1	2.42 ± 2.02	2.38 ± 2.09	0.965
Maximal tumor size1	4.20 ± 2.06	5.44 ± 5.36	0.444
Beyond Milan criteria	9 (75.0)	17 (65.4)	0.714
Time between LDLT and recurrence, median	6 (range: 3-150)	5 (range: 1-46)	0.270
Patterns of HCC recurrence
Single or Multiple			0.219
Single	2 (16.7)	1 (3.7)
Multiple	10 (83.3)	26 (96.3)
Intrahepatic or Extrahepatic			0.074
Intrahepatic	0	9 (33.3)
Extrahepatic	10 (83.3)	15 (55.6)
Both	2 (16.7)	3 (11.1)
AFP at HCC recurrence1	7913.2 ± 16023.5	6139.5 ± 17794.2	0.772

¹Values are shown as mean ± SD except where stated otherwise. MELD: Model for end-stage liver disease; GRWR: Graft-to-recipient body weight ratio; AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma; LDLT: Living donor liver transplantation.